StockDuty ← Dashboard Nov 14, 2026 05:39 AM ET
SignalEarnings

$BSX (BOSTON SCIENTIFIC) — 8-K: BSX Q3 FY26: Adj EPS $0.73 beats consensus $0.72 (+0.9%); revenue $5.14B +1.4% YoY

BSX
$44.34
+0.32%
Boston Scientific delivered a modest beat with Q3 FY26 adjusted EPS of $0.73 versus the $0.72 street consensus, a +0.9% beat. Revenue came in at $5,138M, up 1.4% YoY, with Cardiovascular +1.9% and MedSurg +0.6%. FY2026 adjusted EPS guidance is $3.16-$3.18, and Q4 FY26 adjusted EPS is guided to $0.77-$0.79. Management flagged a challenging year, citing a cybersecurity incident first reported August 26, 2026 as a headwind to operations and results.
Boston Scientific delivered a modest beat with Q3 FY26 adjusted EPS of $0.73 versus the $0.72 street consensus, a +0.9% beat. Revenue came in at $5,138M, up 1.4% YoY, with Cardiovascular +1.9% and Med
Sources